Masita Wulandari Suryoputri

Masita Wulandari Suryoputri

Auto-generated profile, based on publicly available information

Masita Wulandari Suryoputri

Laboratory of Pharmacology and Clinical Pharmacy, Faculty of Health Sciences, Universitas Jenderal Soedirman, Purwokerto

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2022 in Acta Pharmaciae Indonesia : Acta Pharm Indo
Verified
Journal Article
Open access
PDF file
HEHeny Ekowati
Heny Ekowati
FNFaradina Qorina Nadzif
Faradina Qorina Nadzif
MSMasita Wulandari Suryoputri
Masita Wulandari Suryoputri
Background: COVID-19 is associated to an oxidant-antioxidant imbalance, which leads to inflammation and tissue damage. N-Acetylcysteine (NAC), in addition to being a mucolytic, has been shown to be an effective antioxidant in the therapy of COVID-19. Objective: The purpose of this study is to evaluate at the NAC usage profile in COVID-19 inpatients at Santa Elisabeth Hospital in Purwokerto. Methods: A descriptive observational design was used to perform the study. Retrospective data were obtained from medical records from July 2020 to July 2021. All patients who met the inclusion criteria were sampled using the total sampling technique. Results: NAC was commonly administered to COVID-19 inpatients who have a mild illness of the disease. The most common symptoms were cough and fever. Patients with mild and moderate severity were given NAC orally (600 mg 3 times a day) and intravenously (5 gram/day), respectively. The duration of NAC administration was in the range of 8-14 days. Conclusion: NAC was one of the therapies used at Santa Elisabeth Hospital Purwokerto for COVID-19 inpatients.

1 August 2022 in Acta Pharmaciae Indonesia : Acta Pharm Indo
Verified
Journal Article
Open access
PDF file
PPPurgiantari Purgiantari
Purgiantari Purgiantari
MSMasita Wulandari Suryoputri
Masita Wulandari Suryoputri
NENialiana Endah Endriastuti
Nialiana Endah Endriastuti
Background: Adherence is one of the most critical factors in the success of pulmonary tuberculosis therapy. Non-compliance of patients taking anti-tuberculosis drug results in a high rate of treatment failure, increasing the risk of disease severity and death. Objective: This study aims to investigate the impact of knowledge level on patient compliance in taking anti-tubercular medication. Methods: This observational, cross-sectional study employed a total sampling method. The levels of knowledge and compliance were assessed using a validated questionnaire administered to patients with pulmonary tuberculosis at the Pekalongan City health center (Puskesmas). Results: Among the 52 participants, 44.23% (n=23) demonstrated a high level of knowledge, and 86.5% (n=45) exhibited good compliance. Spearman correlation test analysis revealed a significant influence of knowledge level on patient compliance in taking antituberculosis drugs (p=0.001, r=0.341), indicating that higher knowledge levels correspond to better patient compliance. Conclusion: The study suggests that patient compliance with antitubercular medication improves as knowledge level increases.

4 December 2023 in JPSCR: Journal of Pharmaceutical Science and Clinical Research
Verified
Journal Article
Open access
PDF file
MSMasita Wulandari Suryoputri
Masita Wulandari Suryoputri
DIDewi Latifatul Ilma
Dewi Latifatul Ilma
NENialiana Endah Endriastuti
Nialiana Endah Endriastuti
Gentamisin merupakan obat dengan indeks terapi sempit yang perlu dilakukan pemantauan kadar obat dalam darah karena dapat berpengaruh pada luaran klinis pasien. Penelitian ini bertujuan untuk mengetahui hubungan kadar gentamisin dengan outcome clinic pada pasien anak yang menderita pneumonia. Perhitungan kadar gentamisin dalam darah dapat dilakukan secara farmakokinetika berdasarkan dosis dan frekuensi pemberian obat menggunakan rumus matematika. Penelitian ini merupakan penelitian dengan desain observasional dan retrospektif. Pengumpulan data dilakukan selama 3 bulan di Instalasi Rekam Medik RSUD Ajibarang. Pengambilan data secara total sampling yang memenuhi kriteria inklusi dan eksklusi. Analisis data statistik menggunakan uji chi square untuk mengetahui hubungan kadar gentamisin dengan outcome clinic responden. Hasil penelitian ini menunjukkan terdapat 52 responden (96,3%) memiliki kadar Cssave sesuai kisaran terapi (0,5-10mg/L) dan 2 responden (3,7%) memiliki kadar Cssave tidak sesuai kisaran terapi. Dari 52 responden yang memiliki kadar Cssave sesuai kisaran terapi (0,5-10mg/L) terdapat 21 responden memberikan outcome clinic membaik dan 31 responden memberikan outcome clinic belum membaik, sedangkan 2 responden yang memiliki kadar Cssave tidak sesuai kisaran terapi terdapat 1 responden memberikan outcome clinic membaik dan 1 responden memberikan outcome clinic belum membaik. Kesimpulan: berdasarkan perhitungan estimasi kadar obat gentamisin, tidak terdapat hubungan yang signifikan antara kadar Cssave gentamisin dengan outcome clinic pasien anak penderita pneumonia di RSUD Ajibarang (p>0.05).

31 March 2022 in Acta Pharmaciae Indonesia : Acta Pharm Indo
Verified
Journal Article
Open access
PDF file
NENialiana Endah Endriastuti
Nialiana Endah Endriastuti
MSMasita Wulandari Suryoputri
Masita Wulandari Suryoputri
DIDewi Latifatul Ilma
Dewi Latifatul Ilma
TPTunggul Adi Purwonugroho
Tunggul Adi Purwonugroho
Background: The trend of using nutraceuticals in Indonesia increases every year. This study aims to describe nutraceuticals consumed in pediatrics with epilepsy as additional antiepileptic therapy and analyze their potential drug interactions. Methods: This research was a cross-sectional study with total sampling method which was carried out in the period of June to July 2020. Inclusion criteria were children with epilepsy aged 0-17 years who were members of the Indonesian Epilepsy Community, had a doctor's diagnosis of epilepsy, received oral antiepileptic medication, and took nutraceutical products/food supplements. Data were analyzed descriptively based on data obtained through electronic data filling sheets and interviews. Results: There were 106 participants from the Indonesian Epilepsy Community in total, with 14 children (13.2 %) using nutraceutical supplements. They were male (n=8; 57.1%), 2-12 years old (n=10; 71.4%), and good nutritional status (n=10; 71.4%). Most nutraceuticals consumed were dietary supplements containing vitamins (n=10; 71.4%). Of the eight potential drug interactions identified, 25% (n=2) were significant interactions, and 75% (n=6) were minor interactions. The potential for major interactions occurred in administering nutraceutical products containing vitamin D with the antiepileptic drug phenytoin and phenobarbital. Conclusion: In this study, nutraceuticals and antiepileptic drugs had a little clinically meaningful interaction effect.

4 February 2023 in Acta Pharmaciae Indonesia : Acta Pharm Indo
Verified
Journal Article
Open access
PDF file
HEHeny Ekowati
Heny Ekowati
FNFaradina Qorina Nadzif
Faradina Qorina Nadzif
MSMasita Wulandari Suryoputri
Masita Wulandari Suryoputri
NENialiana Endah Endriastuti
Nialiana Endah Endriastuti
HBHanif Nasiatul Baroroh
Hanif Nasiatul Baroroh
Background: COVID-19 has been associated with increased innate immune system activation, leading to increased mucus production, inflammation, and tissue damage. N-Acetylcystysteine (NAC), an antioxidant and mucolytic, has demonstrated potential as a COVID-19 therapy. Objective: The purpose of this study was to evaluate the effectiveness of NAC on the clinical symptoms of hospitalized COVID-19 patients at Santa Elisabeth Purwokerto General Hospital in Indonesia. Methods: An observational analytical study design was employed, with data collected from the medical records of hospitalized COVID-19 patients at Santa Elisabeth Purwokerto General Hospital over the period of July 2020 to July 2021. The study included 209 patients who met the eligibility criteria. Results: The results indicated that the use of NAC affected the clinical symptoms of cough, oxygen saturation (SPO2), and respiratory rate in patients with mild and moderate degrees of COVID-19 patients (p0.05). Conclusion: This study suggests that NAC may be a useful treatment option for patients with mild and moderate COVID-19. Further research is needed to confirm these findings and determine their effectiveness in severe cases.

1 January 2025 in Acta Pharmaciae Indonesia : Acta Pharm Indo
Verified
Journal Article
Open access
PDF file
APAtika Putri
Atika Putri
DIDewi Latifatul Ilma
Dewi Latifatul Ilma
MSMasita Wulandari Suryoputri
Masita Wulandari Suryoputri
NENialiana Endah Endriastuti
Nialiana Endah Endriastuti
Background: Anticoagulants are essential for stroke prophylaxis in atrial fibrillation but carry significant interaction potential with commonly used medications. Understanding the prevalence and patterns of these interactions is crucial for optimizing therapy. Objective: To assess the incidence and characteristics of potential drug-drug interactions (DDIs) in hospitalized atrial fibrillation patients receiving anticoagulant therapy. Methods: This retrospective, descriptive observational study analyzed medical records of 324 atrial fibrillation patients hospitalized between January 2019 and December 2021 at a regional hospital in Banyumas Regency. Potential DDIs were assessed using Lexicomp, Drugs.com, and Merck Manual databases, and categorized by severity, mechanism, and clinical manifestation. Results: Nearly all patients (98.90%) experienced at least one potential DDI. Of 1,249 identified DDI events, most were moderate in severity (83.27%) and primarily involved warfarin (69.73%). Pharmacodynamic mechanisms predominated (51.24%), and decreased anticoagulant efficacy was the most common potential clinical manifestation (64.21%). Warfarin accounted for most pharmacokinetic (10.49%) and pharmacodynamic (32.42%) interactions. Elderly patients (>65 years) constituted the largest population group (40.74%), and most patients (65.74%) had atrial fibrillation as a secondary diagnosis. Conclusion: The high prevalence of potential DDIs involving anticoagulants in hospitalized atrial fibrillation patients underscores the need for vigilant medication management, particularly for patients receiving warfarin and those with multiple comorbidities.